CurrentCapital BluecrossPolicy AHS - G2055 - Prenatal Testing for Fetal Aneuploidy

Prenatal Testing for Fetal Aneuploidy

Defines coverage criteria for prenatal screening and diagnostic tests to assess fetal aneuploidy (common trisomies and sex chromosomes) for pregnant individuals, and lists tests considered investigational or not covered. Applies to Capital Bluecross members in North Carolina.

Policy Summary

PayerCapital Bluecross

PolicyPrenatal Testing for Fetal Aneuploidy

Policy CodePolicy AHS - G2055 - Prenatal Testing for Fetal Aneuploidy

Change TypeNo material change

Effective Date

Next Review DateMay 1, 2026

Key ActionDocument gestational age, test modality, and counseling; offer genetic counseling and diagnostic testing for positive or no-call results.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥10wMin GA for NIPS

11-14w1st-trimester window

15-22w2nd-trimester window

13,18,21,X,YTrisomies covered

>3.0 mm

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Prenatal Testing

inv-01: Covered tests and pathways

Covered when the following conditions are met:

Standard serum/NT screening: First- and/or second-trimester maternal serum screening tests that detect fetal aneuploidy of chromosomes 13, 18, and 21 meet coverage criteria when performed in specified gestational windows: first trimester 11-14 weeks with hCG, PAPP-A and nuchal translucency (NT); second trimester 15-22 weeks with triple (hCG, AFP, uE3 with NT) or quad (hCG, AFP, uE3, DIA with NT); and integrated, sequential, or contingent combinations as described in policy.gestational windows as defined

Includes contingent/sequential/integrated approaches.

Noninvasive prenatal screening (NIPS): NIPS using cell-free fetal DNA to detect aneuploidy of chromosomes 13, 18, 21, X, and Y in singleton or twin pregnancies of at least 10 weeks gestation meets coverage criteria.>=10 weeks gestation

High sensitivity/specificity; positive results should be confirmed with invasive diagnostic testing.

Diagnostic confirmation: Karyotyping to confirm fetal aneuploidy is covered to pursue confirmation of equivocal or positive screening test results.N/A

Diagnostic invasive testing (CVS or amniocentesis) is the appropriate confirmatory test.

inv-02: Not medically necessary / investigational

Not covered / investigational in the following circumstances:

Not covered tests or uses: Use of the 'penta' screen (including hyperglycosylated hCG), single-cell genotyping in trophoblasts isolated from maternal serum (e.g., Luna Prenatal Test), screening for other chromosomal abnormalities (microdeletions, unbalanced translocations, deletions, duplications), determination of fetal sex, parallel or simultaneous multiple screening methodologies, screening of higher-order multiple gestations, and repeat screening after negative results do not meet coverage criteria.N/A

These tests/uses are considered investigational or excluded from coverage.

inv-03: Covered with criteria: Prenatal aneuploidy screening and required follow-up

Coverage and clinical management aligned with ACOG/SMFM recommendations (Level A–C):

Offer and discuss screening/diagnostic options: Prenatal genetic screening (serum screening with or without nuchal translucency ultrasound or cell-free DNA screening) and diagnostic testing (CVS or amniocentesis) should be discussed and offered to all pregnant individuals regardless of maternal age or baseline risk; patients may accept or decline after counseling.

ACOG/SMFM Level A recommendation

Single screening approach: If screening is accepted, patients should have one prenatal screening approach and should not have multiple screening tests performed simultaneously.

Avoid redundant simultaneous screening

NIPS performance and limitation counseling: Cell-free DNA is the most sensitive and specific screening test for common fetal aneuploidies but is not diagnostic; it can produce false-positive and false-negative results and positive screens require confirmatory diagnostic testing.

Counsel patients regarding limitations

inv-04: Covered Clinical Criteria

Covered when counseling and appropriate testing offer/documentation occur; specific clinical recommendations from professional societies guide testing selection.

Universal Offer: Offer discussion of prenatal genetic screening (serum screening with/without NT or cfDNA) and diagnostic testing (CVS or amniocentesis) to all pregnant individuals regardless of maternal age or baseline risk.

Patients have the right to accept or decline

Single Screening Approach: If screening is accepted, perform only one prenatal screening approach; do not perform multiple screening tests simultaneously.

Avoids high positive rates and conflicting risk estimates

Positive Screening Follow-up: Patients with a positive screening test should receive genetic counseling, comprehensive ultrasound evaluation, and be offered diagnostic testing to confirm results.

Includes cfDNA positive results and ultrasound findings

Coverage excludes certain specific tests and testing approaches. The use of a penta screen (including hyperglycosylated hCG) and single-cell trophoblast genotyping from maternal serum (for example, the Luna Prenatal Test) does not meet coverage criteria. Parallel or simultaneous use of multiple independent screening methodologies, screening higher-order multiple gestations, repeat screening after a negative result, screening for other chromosomal abnormalities beyond those specified, and determination of fetal sex are also excluded from coverage.

Noninvasive prenatal screening (NIPS) does not detect neural tube defects. When neural tube defect detection is desired, offer maternal serum alpha-fetoprotein (AFP) testing in the second trimester to pregnant individuals who had first‑trimester aneuploidy screening. This aligns with the policy note that NIPS cannot replace traditional second‑trimester screening components for neural tube defect assessment.

Professional guidance advises against routine screening for certain less‑studied trisomies. ACOG specifically recommends against screening for trisomies such as trisomy 16 or 22 because of a lack of validated data supporting clinical utility. Extension of NIPT to rare autosomal trisomies and some sex chromosome aneuploidies remains controversial due to limited performance data.

The policy implicitly excludes reliance on NIPS results alone for definitive clinical decision‑making. The FDA has communicated that NIPS are laboratory‑developed screening tests that may give false results, and health care providers should not use NIPS results alone to diagnose chromosomal abnormalities. Confirmatory diagnostic testing is recommended for positive or suspicious screening results.

Screening for additional genetic conditions beyond the specified common aneuploidies—such as other aneuploidies, microdeletions/microduplications, unbalanced translocations, deletions, duplications, and certain novel or expanded panels—is considered investigational and does not meet coverage criteria.

NIPT/NIPS is a screening modality and is not diagnostic. It cannot replace invasive diagnostic testing (CVS or amniocentesis with karyotype or microarray) when a definitive diagnosis is required to determine the aneuploidy type, counsel about recurrence risk, or guide clinical management.

Using NIPS results alone to make diagnostic conclusions is inappropriate. The FDA safety communication emphasizes that NIPS tests have not been evaluated by the FDA for diagnostic performance and can produce false‑positive or false‑negative results; therefore, confirmatory diagnostic testing should be offered before making pregnancy‑altering clinical decisions.

Procedure and Billing Codes

Applicable CPT/HCPCS procedure codesmixed

No codes listed

Referenced CPT/HCPCS Codesmixed

81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21.
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy (Harmony™ referenced).
81508	Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG), utilizing maternal serum, algorithm reported as a risk score.
81509	Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG, DIA), utilizing maternal serum, algorithm reported as a risk score.
81510	Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG), utilizing maternal serum, algorithm reported as a risk score.
81511	Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG, DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing).
81512	Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal serum, algorithm reported as a risk score.
82105	Alpha-fetoprotein (AFP); serum.
82106	Alpha-fetoprotein (AFP); amniotic fluid.
82677	Estriol.

1–10 of 20

1/2

Minimum gestational age for NIPS

Minimum gestational age for NIPS>= 10 weeks gestation

Earliest detection noted in literaturecffDNA detectable as early as ~4.5 weeks, routinely detectable by 6–7 weeks

Fetal fraction at 10 weeksAt 10 weeks fetal fraction comprises at least 3–4% of total cfDNA

Enlarged nuchal translucency

Enlarged NT threshold> 3.0 mm (99th percentile)

NT percentile criteria>= 95th percentile corresponds to ≥ 3.0 mm

Provider Responsibilities, Documentation, and Billing Actions

Documentation Required

Coverage Criteria and Required Documentation

Coverage for prenatal aneuploidy testing requires that test-specific clinical criteria are met and documented. Providers must document the gestational age at time of testing and the testing pathway chosen (for example: first‑trimester serum+NT, second‑trimester quad, integrated/contingent/sequential approaches, or NIPT). Do not perform parallel or simultaneous independent screening approaches.

Document gestational age and timing of any prior or concurrent screens when ordering tests.
Document the specific assay/platform used for NIPT and that counseling/informed consent was provided.
Single screening approach: patients should have one prenatal screening strategy; avoid multiple independent serum or cfDNA screens.

Billing Rule

Billing and Prior Authorization Verification

Background and Context

Fetal aneuploidy refers to abnormalities in chromosome number, most commonly trisomies 21, 18, and 13, and can result in pregnancy loss or congenital anomalies. Traditional maternal serum with or without nuchal translucency (NT) screening provides moderate detection rates with some false positives, whereas cell‑free fetal DNA–based NIPS offers higher sensitivity and specificity for the common trisomies and can be performed earlier in pregnancy. Regardless, positive screening results require genetic counseling, comprehensive ultrasound evaluation, and confirmatory invasive diagnostic testing to establish a definitive diagnosis and inform counseling and management.

Key Definitions and Test Modalities

cffDNA / NIPS / NIPT — definition and brief description

DefinitionCell-free fetal DNA (cffDNA) detected in maternal plasma used for noninvasive prenatal screening/testing to estimate risk of fetal aneuploidy

PurposeScreening method to estimate increased or decreased risk for common fetal aneuploidies (eg, trisomies 13, 18, 21; sex chromosomes)

Diagnostic limitationNIPS is a screening test and does not provide a definitive diagnosis; positive results should be confirmed with invasive diagnostic testing

Nuchal translucency (NT) — definition and clinical relevance

DefinitionNuchal translucency (NT) is an ultrasound measurement of the fluid-filled space at the dorsal aspect of the fetal neck in the first trimester

Clinical relevance

Policy Summary

PayerCapital Bluecross

PolicyPrenatal Testing for Fetal Aneuploidy

Policy CodePolicy AHS - G2055 - Prenatal Testing for Fetal Aneuploidy

Change TypeNo material change

Effective Date

Next Review DateMay 1, 2026

Key ActionDocument gestational age, test modality, and counseling; offer genetic counseling and diagnostic testing for positive or no-call results.

SourceLink

On This Page

Ultrasound and AFP offer: All patients should be offered a second-trimester ultrasound for fetal structural defects, ideally at 18–22 weeks, with or without second-trimester maternal serum AFP.

Structural assessment irrespective of aneuploidy screening

Positive screen follow-up: Patients with a positive screening test result should undergo genetic counseling, comprehensive ultrasound evaluation, and be offered diagnostic testing to confirm results.

Confirmatory diagnostic testing recommended

Negative screen counseling: Patients with a negative screening result should be informed that risk is substantially decreased but not eliminated; other genetic disorders not evaluated may be present and diagnostic testing may be chosen later if indicated.

Ongoing counseling

No-call result management: Uninterpretable or no-call cell-free DNA results should prompt counseling, recognition of increased aneuploidy risk, and offer of comprehensive ultrasound evaluation and diagnostic testing (consider repeat draw where appropriate).

No-call associated with increased aneuploidy risk

No-call / Uninterpretable cfDNA: If cfDNA results are not reported or are uninterpretable (no-call), inform patient of increased aneuploidy risk, provide genetic counseling, and offer comprehensive ultrasound and diagnostic testing; consider repeat cfDNA draw when appropriate.

Follow ACOG/NSGC guidance

Ultrasound recommendations: Offer second-trimester anatomy ultrasound (ideally 18-22 weeks) to all patients regardless of screening decisions; perform detailed ultrasound if NT enlargement or anomalies are identified.

Structural assessment per NSGC/ACOG

Twin and multifetal gestations: Inform patients that serum-based screening is less accurate in multifetal gestations; cfDNA may be performed but has limitations and test interpretation should consider chorionicity/zygosity and fetal fraction. Offer diagnostic testing when fetal demise, vanishing twin, or anomaly is present.

Counsel regarding limitations in multifetal pregnancies

ACMG recommendations: ACMG recommends offering NIPS over traditional screening for trisomies 21, 18, and 13 in singleton and twin gestations, offering NIPS for sex chromosome aneuploidies, and selective offering for 22q11.2 deletion; routine screening for other CNVs or rare autosomal trisomies is not supported by sufficient evidence.

Incorporate ACMG guidance into shared decision-making

Clinical association

Enlarged NT is independently associated with increased risk of aneuploidy and structural malformations

Nuchal translucency — clinical thresholds and follow-up

Threshold for offering diagnostic testingNT ≥ 95th percentile or ≥ 3.0 mm — offer diagnostic testing (CVS or amniocentesis)

Fetal echocardiogram recommendationConsider referral for fetal echocardiogram if NT ≥ 3.5 mm

Follow-up actions for enlarged NTProvide genetic counseling, comprehensive ultrasound evaluation, and offer diagnostic testing to confirm results

Certain procedure codes listed in the policy may be subject to prior authorization or payer-level requirements. Verify prior authorization requirements before ordering or billing specific CPT/HCPCS codes.

Check PA requirements for cfDNA/NIPT procedure codes (e.g., 81420, 81507, 0327U) and for associated maternal serum analyte codes (81508–81512, 82105, 82106, 82677, 84163, 84704, 86336).
When ordering NIPT, record the exact test name/platform in the medical record (e.g., Harmony, Panorama, Verifi, Visistera, Vanadis, NIFTY) to support medical necessity and billing.

Prior Authorization

Prior Authorization for Specific NIPT Platforms

Some commercial expanded NIPT platforms or proprietary panels may require prior authorization. Confirm payer-specific prior authorization policies for specific NIPT platforms prior to testing.

Proprietary tests referenced in the policy (e.g., Harmony, Panorama, Vasistera) may have specific coverage rules or PA requirements—verify with Capital BlueCross prior to ordering.
If a PA is required, include documentation of counseling, gestational age, and indications supporting test selection.

Documentation Required

Test Failure / No‑Call Risk and Follow-Up

NIPT may yield uninterpretable or no‑call results due to low fetal fraction or other technical issues. Providers should counsel patients about test-failure risk and document counseling and follow-up plans.

Inform patients that low fetal fraction (more likely at early gestational ages and with high BMI) can cause no‑call results; document that counseling occurred.
For no‑call results, document offering genetic counseling, repeat testing only when appropriate, comprehensive ultrasound, and consideration of diagnostic testing.

Documentation Required

Diagnostic Confirmation Pathway

When NIPT or other screening tests are positive or equivocal, diagnostic confirmation is required via invasive testing (karyotype from CVS or amniocentesis). Document counseling about diagnostic options and the plan for confirmatory testing.

Positive or equivocal screening results should be confirmed with karyotyping (CVS or amniocentesis) prior to any irreversible clinical decisions.
Document genetic counseling, ultrasound findings, and the patient’s informed decision regarding confirmatory diagnostic testing.

Note

Stepwise Testing Option and Counseling

Stepwise testing is an acceptable approach: using cfDNA (NIPT) as a follow-up after a screen‑positive maternal serum analyte test is an option but requires counseling about implications and limitations. Document counseling and the chosen pathway.

If using cfDNA as a secondary screen after a positive serum screen, document the initial result, counseling provided, and rationale for the stepwise approach.
Patients should be counseled that cfDNA remains a screening test and positive results still require diagnostic confirmation.

Prior Authorization

Government Policy Precedence

Government policies (LCDs/NCDs/state Medicaid) take precedence when there is a conflict with this policy. Verify applicable government coverage rules for the member before finalizing test orders or claims.

When member coverage is Medicare or Medicaid, review relevant Local Coverage Determinations (LCDs), National Coverage Determinations (NCDs), and state Medicaid rules.
If a government policy differs from this policy, the government policy will determine coverage.

Denial Risk

Risk from False Results and Counseling

NIPT and other cfDNA screening tests have potential for false‑positive and false‑negative results. Counsel patients about residual risk and the need for diagnostic confirmation when screening results are positive or when clinical findings suggest anomalies.

Provide and document informed consent that explains the possibility of false results and limitations of screening versus diagnostic tests; reference FDA safety communications as appropriate.
Ensure documentation of genetic counseling and shared decision‑making in the medical record for positive, negative, or no‑call results.

Step Therapy

No step therapy requirements are specified in this policy for prenatal aneuploidy testing.

There is no explicit step therapy pathway mandated by this policy; follow the clinical guidance and any payer-specific PA rules instead.

Enlarged NT (>3.0 mm or ≥ 95th percentile) is associated with increased risk of fetal aneuploidy and structural malformations

Use in screeningNT is used with first-trimester serum markers to improve screening accuracy for aneuploidy

Massively parallel sequencing (MPS) — definition

DefinitionMassively parallel sequencing (MPS) sequences millions of maternal and fetal chromosome fragments to quantify and detect aneuploidies

PerformanceMPS can detect common aneuploidies with high sensitivity and specificity (eg, high detection rates for trisomies 21, 18, 13)

Method noteMPS involves broad sequencing of cfDNA rather than selective locus analysis

SNP-based NIPS — definition and implications for confirmation

DefinitionSNP-based NIPS analyzes selected single nucleotide polymorphisms on chromosomes of interest to detect aneuploidy

Implication for confirmationAlthough validated, SNP-based approaches may require ultrasound or invasive confirmation due to possible placental–fetal discordance (eg, confined placental mosaicism)

False-positive causeDiscordance between placenta-derived cfDNA and fetal genotype can lead to false positives in SNP-based methods

No-call / test failure — definition and clinical implications

DefinitionA 'no-call' or test failure is an uninterpretable laboratory report often due to low fetal fraction or insufficient cfDNA

Clinical implicationNo-call results are associated with an increased risk of aneuploidy and should prompt counseling, comprehensive ultrasound evaluation and offer of diagnostic testing; repeat draw may be considered

ContributorsEarly gestational age (<10 weeks) and high maternal BMI are factors associated with low fetal fraction and test failure

Confined placental mosaicism (CPM) — explanation of discordant results cause

DefinitionConfined placental mosaicism (CPM) is a condition in which the genetic status of the placenta differs from that of the fetus, potentially causing discordant NIPS results

Result impactCPM can produce false-positive NIPS results when placental cfDNA carries aneuploidy not present in the fetus

Diagnostic considerationWhen discordant results occur, invasive diagnostic testing and placental assessment may clarify the etiology

NIPS / NIPT / NIPD — umbrella definition emphasizing screening (not diagnostic)

Umbrella definitionNIPS/NIPT/NIPD refers to noninvasive prenatal screening/testing/diagnosis using circulating cfDNA from maternal blood to assess fetal chromosomal aneuploidy

Screening vs diagnosticThese tests are screening methods and are not diagnostic; positive or suspicious results warrant confirmatory invasive testing

Regulatory noteMany NIPT assays are laboratory-developed tests performed under CLIA and are not FDA-approved; FDA cautions about false results

First/Second trimester serum screens (triple/quad/penta/integrated)

Triple screenA second-trimester maternal serum panel measuring three markers (eg, AFP, hCG, uE3) to screen for aneuploidy

Quad screenSecond-trimester panel of four markers: AFP, hCG, uE3, and inhibin A (DIA), commonly used 15–22 weeks

Integrated/combined approachesIntegrated, sequential, or contingent combinations of first- and second-trimester serum screening (with or without NT) are used to maximize detection rates

NIPT / cell-free DNA (cfDNA) screening — restated definition and purpose

DefinitionNIPT/cell-free DNA (cfDNA) screening analyzes fetal-derived cfDNA in maternal plasma to assess risk for common fetal chromosomal aneuploidies

Gestational timingCan be performed at any gestational age after approximately 9–10 weeks; fetal fraction increases with gestation

Test characteristicsHigh detection rate for trisomy 21 (~99%) with low screen-positive rate (2–4%); however, results may reflect maternal aneuploidy or other maternal disease